Robin Penugula Lazarus
Robin's research deals with evaluation of immune responses to rotavirus infection and vaccination in Indian infants supplemented with zinc and probiotics. Two live, orally administered rotavirus vaccines, RotaTeq® (RV5; Merck and Co, Inc, Pennsylvania, United States) and Rotarix™ (RV1; GSK Biologicals, Rixensart, Belgium), are licensed and used in many countries worldwide. The aim of his study is to elucidate the role of the systemic immune response in rotavirus infection and vaccination, and specifically to evaluate whether two potentially immunomodulatory interventions, zinc and probiotics, can affect the immune response and viral replication. While it is unknown if improved immune response to rotavirus results in an improved performance of the vaccine, this study will provide evidence for whether larger effectiveness evaluations of these interventions should be pursued.